ATC codes:
L01CD02
Indication
Malignant neoplasms of prostate
ICD11 code:
2D32.Z
INN
Docetaxel
Medicine type
Chemical agent
List type
Complementary
Formulations
Parenteral > General injections > IV:
20 mg per mL ;
40 mg per mL
Sex
All
Age
Adolescents and adults
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for docetaxel on the complementary list of the EML for use in treatment protocols for metastatic prostate cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for metastatic prostate cancer is attached.